Clinical study to assess the efficacy and safety of maraviroc in coronavirus lung infection (COVID-19).

Registry ID

EUCTR2020-002011-21

Source registry

EUCTR

Status

Ongoing

Phase

PHASE2

Sponsor

Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor y Sureste (FIIB)

Start date

2020-06-02

Last update

2026-08-16

Conditions

• COVID-19 Pneumonia

Summary

To compare the efficacy of Maraviroc (MRV) associated with standard treatment according to local guidelines vs. standard treatment alone in terms of progression to severe adult respiratory distress syndrome (ARDS).

Locations

• , , Spain

Related clinical trials

• Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
• Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
• Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
• Corona Virus Disease 2019 Cohort Study
• Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan

View on source registry